![conference banner](/images/conference-banner.jpeg)
Abstract
The coronavirus disease 2019 (Covid-19) pandemic has been considered a major threat to human health. Effective therapeutic approaches are urgently required. Spike protein and the Angiotensin-converting enzyme 2 (ACE2) receptors have critical roles in SARS-CoV-2 infection. As a result, these two proteins are considered potential targets for the development of a wide variety of biotherapeutics and vaccines for controlling Covid-19. The fusion proteins have desirable medicinal properties, including high serum half-life, stability, and solubility in the body. Moreover, other Fc-fusion proteins used to treat other diseases have no known side effects. These Fc-fusion proteins are valuable biopharmaceuticals and have been proposed as therapeutic candidates for the treatment and prevention of Covid-19 owing to their potential therapeutic benefits.
Keywords: Fc-fusion proteins, Covid-19, SARS-CoV-2, Spike protein, ACE2, receptor.
[http://dx.doi.org/10.3389/fpls.2021.682953] [PMID: 34054909]
[http://dx.doi.org/10.1136/bmj-2021-068373] [PMID: 35296468]
[http://dx.doi.org/10.1007/s11684-021-0913-y] [PMID: 35226300]
[http://dx.doi.org/10.1016/j.cell.2020.03.045] [PMID: 32275855]
[http://dx.doi.org/10.1016/j.bios.2020.112868] [PMID: 33281048]
[http://dx.doi.org/10.1002/biot.202000566] [PMID: 33481336]
[http://dx.doi.org/10.1021/acscentsci.1c00120] [PMID: 34056083]
[http://dx.doi.org/10.1016/j.talanta.2022.123519]
[http://dx.doi.org/10.1016/j.vaccine.2020.06.066] [PMID: 32651113]
[http://dx.doi.org/10.1007/s40259-015-0133-6] [PMID: 26177629]
[http://dx.doi.org/10.1002/jps.23984]
[http://dx.doi.org/10.1016/j.tibtech.2014.11.001] [PMID: 25488117]
[http://dx.doi.org/10.1002/jssc.202000765] [PMID: 32914936]
[http://dx.doi.org/10.1002/emmm.201201379]
[http://dx.doi.org/10.3389/fimmu.2017.01860] [PMID: 29375551]
[http://dx.doi.org/10.1007/s00705-014-2163-7] [PMID: 25008896]
[http://dx.doi.org/10.1371/journal.pone.0237295] [PMID: 32756606]
[http://dx.doi.org/10.1016/j.ijbiomac.2020.10.1205] [PMID: 33080267]
[http://dx.doi.org/10.15252/emmm.202012828] [PMID: 33159417]
[http://dx.doi.org/10.1186/s13054-017-1823-x] [PMID: 28877748]
[http://dx.doi.org/10.1183/13993003.02638-2017] [PMID: 29903860]
[http://dx.doi.org/10.1016/j.kint.2018.01.029] [PMID: 29691064]
[http://dx.doi.org/10.1016/j.celrep.2020.108528] [PMID: 33326798]
[http://dx.doi.org/10.1016/j.omtm.2021.05.004] [PMID: 34007862]
[http://dx.doi.org/10.3389/fpls.2020.604663] [PMID: 33584747]
[http://dx.doi.org/10.1016/j.bbrc.2004.09.106] [PMID: 15474494]
[http://dx.doi.org/10.1039/D0CC03263H] [PMID: 32613971]
[http://dx.doi.org/10.1016/j.vaccine.2020.09.058] [PMID: 33010978]
[http://dx.doi.org/10.1038/s41423-021-00658-z] [PMID: 33731916]
[http://dx.doi.org/10.1038/s41392-022-01185-7] [PMID: 36115830]
[http://dx.doi.org/10.1016/j.vaccine.2021.09.077] [PMID: 34642088]
[http://dx.doi.org/10.1016/j.vaccine.2022.01.043] [PMID: 35115195]
![Wayfinder Image](/images/wayfinder.jpg)